Egetis Therapeutics AB (publ) Working Capital to Net Assets Ratio
Egetis Therapeutics AB (publ) working capital to net assets ratio. Egetis Therapeutics AB (publ) (EGTX) has a Working Capital to Net Assets ratio of -29.6% as of March 2026. Working capital of Skr-73.60 Million (current assets of Skr163.20 Million minus current liabilities of Skr236.80 Million) is measured against net assets of Skr248.70 Million. A higher ratio indicates strong short-term liquidity financed by the equity base. Check tangible net worth ratio of Egetis Therapeutics AB (publ) to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of Egetis Therapeutics AB (publ) (2008–2025)
Working capital to net assets ratio of Egetis Therapeutics AB (publ) from 2008 to 2025. This chart shows how Egetis Therapeutics AB (publ)'s Working Capital to Net Assets ratio has evolved across 18 annual periods from 2008 to 2025. As of March 2026, the ratio stands at -29.6%, reflecting working capital of Skr-73.60 Million against net assets of Skr248.70 Million SEK. See Egetis Therapeutics AB (publ) (EGTX) defensive interval to measure how many days the company can operate on defensive assets alone.
Egetis Therapeutics AB (publ) Working Capital to Net Assets Ratio by Year (2008–2025)
Egetis Therapeutics AB (publ) working capital to net assets ratio by year from 2008 to 2025. The table below presents the year-by-year Working Capital to Net Assets ratio for Egetis Therapeutics AB (publ) from 2008 to 2025, covering 18 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see Egetis Therapeutics AB (publ) assets under control.
| Year | WC/NA Ratio | Working Capital (SEK) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | 3.7% | Skr12.70 Million | Skr338.70 Million | Skr253.60 Million | Skr240.90 Million | ▼ -31.9 pp |
| 2024 | 35.7% | Skr175.90 Million | Skr492.90 Million | Skr380.10 Million | Skr204.20 Million | ▼ -8.7 pp |
| 2023 | 44.4% | Skr242.00 Million | Skr545.60 Million | Skr345.90 Million | Skr103.90 Million | ▲ +25.0 pp |
| 2022 | 19.4% | Skr98.00 Million | Skr506.20 Million | Skr147.40 Million | Skr49.40 Million | ▼ -2.2 pp |
| 2021 | 21.6% | Skr113.73 Million | Skr527.04 Million | Skr152.90 Million | Skr39.17 Million | ▼ -14.9 pp |
| 2020 | 36.5% | Skr229.73 Million | Skr629.63 Million | Skr299.87 Million | Skr70.14 Million | ▼ -63.5 pp |
| 2019 | 100.0% | Skr244.87 Million | Skr244.88 Million | Skr269.95 Million | Skr25.08 Million | ▼ 0.0 pp |
| 2018 | 100.0% | Skr219.36 Million | Skr219.36 Million | Skr242.04 Million | Skr22.68 Million | ▲ +0.0 pp |
| 2017 | 100.0% | Skr303.71 Million | Skr303.71 Million | Skr315.37 Million | Skr11.66 Million | ▲ +0.0 pp |
| 2016 | 100.0% | Skr389.56 Million | Skr389.56 Million | Skr396.44 Million | Skr6.87 Million | ▼ 0.0 pp |
| 2015 | 100.0% | Skr48.03 Million | Skr48.03 Million | Skr52.36 Million | Skr4.33 Million | ▲ +0.1 pp |
| 2014 | 99.9% | Skr90.61 Million | Skr90.66 Million | Skr103.42 Million | Skr12.81 Million | ▲ +0.1 pp |
| 2013 | 99.9% | Skr46.90 Million | Skr46.95 Million | Skr50.96 Million | Skr4.06 Million | ▼ 0.0 pp |
| 2012 | 99.9% | Skr53.88 Million | Skr53.94 Million | Skr60.40 Million | Skr6.52 Million | ▼ -0.1 pp |
| 2011 | 100.0% | Skr87.52 Million | Skr87.53 Million | Skr91.41 Million | Skr3.89 Million | ▲ +110.1 pp |
| 2010 | -10.1% | Skr-705.58K | Skr6.99 Million | Skr796.90K | Skr1.50 Million | ▼ -13.4 pp |
| 2009 | 3.3% | Skr187.92K | Skr5.64 Million | Skr461.90K | Skr273.98K | ▼ -6.6 pp |
| 2008 | 9.9% | Skr500.00K | Skr5.05 Million | Skr823.56K | Skr323.55K | — |